Paul Nathan
Mount Vernon Cancer Centre, Northwood, UK · The Hospital for Sick Children · Mount Vernon Cancer Centre at Mount Vernon Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Paul Nathan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:14 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06246149 · Adjuvant Tebentafusp in High Risk Ocular MelanomaEuropean Organisation for Research and Treatment of Cancer - EORTC · recruiting · Uveal Melanoma · principal investigator
- N/ANCT05832138 · ONLOOP Trial: Evaluating a New Surveillance and Support System for Survivors of Childhood Cancer in OntarioThe Hospital for Sick Children · not yet recruiting · Survivorship, Cancer, Heart Diseases · principal investigator
- N/ANCT02611739 · Medi-Port Pilot Randomized Controlled TrialThe Hospital for Sick Children · completed · Actively Undergoing Cancer Treatment, 4-9 Years of Age, At Least 1 Month From Diagnosis · principal investigator
- Ph2NCT00873236 · MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney CancerMount Vernon Cancer Centre at Mount Vernon Hospital · unknown · Kidney Cancer · principal investigator
- Ph1NCT00395434 · Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid TumorsMateon Therapeutics · completed · Tumors · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:14 UTC. The ranking covers the 200 most relevant of 194 PubMed records, and a shared surname and initials can bring in a namesake. All 194 on PubMed
- 2,142 citationsRCR 66.8
- Improved survival with MEK inhibition in BRAF-mutated melanoma.N Engl J Med · 20122,097 citationsRCR 54.1
- Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.N Engl J Med · 20141,551 citationsRCR 42.7
- Pazopanib versus sunitinib in metastatic renal-cell carcinoma.N Engl J Med · 20131,527 citationsRCR 42.9
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.N Engl J Med · 20191,120 citationsRCR 41.8
- 1,101 citationsRCR 33.8
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.N Engl J Med · 2021769 citationsRCR 39.3
- 654 citationsRCR 22.3
- Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.J Clin Oncol · 2013633 citationsRCR 15.9
- 502 citationsRCR 16.1